Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TNFerade · 4 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| TNFerade | GENETIC | - |
| TNFerade™ | DRUG | - |
Inclusion Criteria * Age ≥18 years old * Patients with unresectable, locally advanced adenocarcinoma of the pancreas proven by biopsy or cytology (defined as direct extension to the SMA and/or celiac axis with absence of a fat plane between the low-density tumor and these arterial structures, or lo...
Top 20 of 69 competitors
TNFerade is an investigational gene therapy developed by Precigen, Inc. (ticker: PGEN) for the treatment of several types of cancer, including esophageal cancer, melanoma, pancreatic cancer, and rectal cancer. It is designed to deliver a therapeutic gene directly to tumor sites and is being studied in combination with radiation, chemotherapy, and surgery.
TNFerade is being studied for the treatment of esophageal cancer, melanoma, pancreatic cancer, and rectal cancer. It is an investigational gene therapy, meaning it is not yet approved for commercial use. Clinical trials have evaluated it in combination with radiation, chemotherapy, and surgery in these cancer types.
TNFerade is being developed by Precigen, Inc., a biopharmaceutical company that trades under the ticker symbol PGEN. Precigen focuses on gene and cell therapies, and TNFerade is one of its investigational oncology assets.
TNFerade is in Phase 2 clinical development, with one completed Phase 3 trial also conducted. It is an investigational therapy and has not been approved by the FDA for any indication. The Phase 3 trial evaluated TNFerade in pancreatic cancer, while Phase 2 trials covered melanoma, rectal cancer, and esophageal cancer.
TNFerade has been studied in several completed clinical trials. These include NCT00261404 for metastatic melanoma, NCT00137878 for rectal cancer, NCT00051480 for esophageal cancer, and NCT00051467, a Phase 3 trial for unresectable locally advanced pancreatic cancer. All trials were conducted in the United States.
Yes, TNFerade and TNFerade™ refer to the same investigational gene therapy developed by Precigen, Inc. The trademark symbol is simply a stylized version of the name used in official documents and trial titles.